Life Scientist > Health & Medical

Progen PI-88 trials proliferate

06 June, 2002 by Pete Young

Australian biotech Progen Industries has won ethics approval to launch a Phase I human trial for its anti-cancer drug candidate PI-88 in conjunction with established chemotherapy agent Taxotere.


Psoriasis gene cream results published

05 June, 2002 by Tanya Hollis

A Melbourne-developed topical antisense drug has been shown to successfully penetrate human psoriasis lesions, paving the way for better treatment of the disease.


Meditech in deal with UK's SkyePharma

04 June, 2002 by Tanya Hollis

Perth-based Meditech Research has signed an exclusive commercial agreement with British drug company SkyePharma giving the local biotech access to a suite of new patents.


WEHI research suggests alternative MS treatment

03 June, 2002 by Melissa Trudinger

Researchers at the Walter and Eliza Hall Institute have discovered that treatment with cytokine Leukaemia Inhibitory Factor (LIF) can reverse the loss of nerve cells in a mouse model of multiple sclerosis (MS).


Biotron begins cancer detection assay trials

31 May, 2002 by Melissa Trudinger

A new clinical diagnostic assay for prostate cancer detection is starting clinical trials at St Vincent's Clinic in Sydney.


US cancer institute evaluating Peplin drug

31 May, 2002 by Pete Young

The American National Cancer Institute is scheduling advanced appraisals of an Australian anti-cancer drug which has produced impressive results in preliminary trials.


Mimotopes and Baker combine on cardio treatment

28 May, 2002 by Melissa Trudinger

A letter of intent to jointly develop a new class of drugs for the treatment of congestive heart failure and other cardiovascular diseases has been signed by combinatorial and medicinal chemistry company Mimotopes and the Baker Medical Research Institute.


Share price increase follows Biotron's HIV success

28 May, 2002 by Melissa Trudinger

Canberra biotech Biotron has announced that its lead anti-HIV compound, BIT009 has shown inhibition of HIV-1 replication in infected human cells.


Tocovite claims its technology delivers

27 May, 2002 by Melissa Trudinger

Melbourne-based company Tocovite claims an absorption system that it has developed could improve drug delivery through the skin.


US man first to receive Sirtex cancer treatment

24 May, 2002 by Iain Scott

Anti-cancer treatment SIR-Spheres, designed by Sydney-based company Sirtex, has been used on a patient for the first time since it received US Food and Drug Administration (FDA) approval in March this year.


Diabetes research offensive launched

24 May, 2002 by Tanya Hollis

A research and development agreement with the aim of finding an effective treatment for type II diabetes has been signed in Melbourne.


Melbourne researchers discover heart attack gene link

24 May, 2002 by Melissa Trudinger

Australian researchers have determined three genetic loci which are linked to heart attacks.


UQ researchers in bone growth breakthrough

15 May, 2002 by Pete Young

Australian research on sugars which stimulate stem cells to become bone tissue has resulted in a biological paste that promotes healing of fractures and breaks.


Sleep disorder treatments could help heart patients

15 May, 2002 by Daniella Goldberg

Cardiologists may be prescribing sleep disorder treatments to their patients in the next five years, according to reports from the 14th World Congress of Cardiology, held recently in Sydney.


Epilepsy discoveries expand Bionomics patent portfolio

14 May, 2002 by Tanya Hollis

South Australian genomics company Bionomics has expanded its portfolio of potential epilepsy drug targets with the filing of eight new patents.


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd